Merger Investigations - RAPT Therapeutics will be acquired by GlaxoSmithKline LLC for $58.00 per share, with an estimated aggregate equity value of $2.2 billion. The investigation focuses on whether the RAPT Board breached its fiduciary duties by failing to conduct a fair process and whether the deal provides fair value to shareholders [2] - Calavo Growers will be acquired by Mission Produce, Inc. for $27.00 per share, consisting of $14.85 in cash and 0.9790 shares of Mission for each share of Calavo, valuing Calavo at approximately $430 million. The investigation concerns potential breaches of fiduciary duties by the Calavo Board regarding the fairness of the deal [4] - Penumbra will be acquired by Boston Scientific Corporation in a cash and stock transaction valuing Penumbra at $374 per share, with an enterprise value of approximately $14.5 billion. The investigation examines whether the Penumbra Board failed to conduct a fair process and whether the deal consideration is fair [6] - FONAR Corporation will be acquired by FONAR, LLC and FONAR Acquisition Sub, Inc. for $19.00 per share in an all-cash transaction. The investigation looks into whether the FONAR Board breached its fiduciary duties by not ensuring a fair process and fair value for shareholders [8]

Merger Investigations - Penumbra, Inc. is set to be acquired by Boston Scientific Corporation in a cash and stock transaction valuing Penumbra at $374 per share, with an enterprise value of approximately $14.5 billion. The investigation focuses on whether the Penumbra Board breached its fiduciary duties by failing to conduct a fair process and whether the deal provides fair value to shareholders [2] - Calavo Growers, Inc. will be acquired by Mission Produce, Inc., with Calavo stockholders receiving $27.00 per share, consisting of $14.85 in cash and 0.9790 shares of Mission for each share of Calavo. The total enterprise value of the transaction is approximately $430 million. The investigation examines if the Calavo Board breached its fiduciary duties regarding the fairness of the deal [4] - Clearwater Analytics Holdings, Inc. is being acquired by a Permira and Warburg Pincus-led Investor Group for $24.55 per share in cash, amounting to approximately $8.4 billion. The investigation looks into whether the Clearwater Analytics Board failed to conduct a fair process and if the deal consideration is fair for shareholders [6]

Merger Agreements and Investigations - Repare Therapeutics Inc. will be acquired by XenoTherapeutics, Inc. and Xeno Acquisition Corp., with shareholders expected to receive US$1.82 per Common Share and a contingent value right for additional cash payments [2] - Axalta Coating Systems Ltd. is set to be acquired by Akzo Nobel N.V., where shareholders will receive 0.6539 shares of Akzo Nobel stock for each share of Axalta Coating common stock [4] - Blue Foundry Bancorp will be acquired by Fulton Financial Corporation, with each share of Blue Foundry common stock exchanged for 0.6500 shares of Fulton common stock, valuing the transaction at approximately $243 million or $11.67 per share [6] - Golden Entertainment, Inc. will be acquired in a sale-leaseback transaction, with stockholders receiving total consideration of $30.00, including a fixed exchange ratio of 0.902 shares of VICI common stock and a cash distribution of $2.75 per share [8] Investigations on Fiduciary Duties - Investigations are ongoing regarding whether the boards of Repare Therapeutics, Axalta Coating, Blue Foundry Bancorp, and Golden Entertainment breached their fiduciary duties by failing to conduct a fair process in the merger agreements [2][4][6][8]

Core Insights - Farmers National Banc Corp (FMNB) is currently under investigation regarding its merger with Middlefield Banc Corp, which proposes that Middlefield shareholders receive 2.6 shares of FMNB for each Middlefield share [2][4] - Gina A. Richardson, a director at FMNB, purchased 1,833 shares at $12.99 each, increasing her total ownership to 13,823 shares [1][4] - FMNB's stock price is currently at $13.14, reflecting a 1.55% increase, with a trading range over the past year between $16.29 and $11.58, indicating volatility [3][4] Company Overview - FMNB provides a range of banking services and has a market capitalization of approximately $494.68 million [3] - The stock has shown significant trading activity, with a volume of 140,458 shares on NASDAQ, reflecting investor interest amid the ongoing merger investigation [3]

Core Viewpoint - Bleichmar Fonti & Auld LLP is investigating Olo Inc. and its leadership for potential breaches of fiduciary duties related to the company's pending acquisition by Thoma Bravo at a price of $10.25 per share, which values Olo at approximately $2 billion in equity [1][3][4]. Group 1: Company Overview - Olo Inc. operates an open SaaS platform designed for restaurants, facilitating digital commerce operations such as ordering, delivery, engagement, and payments [3]. - Olo's stock is divided into Class A and Class B shares, with Class B shares having ten votes per share compared to one vote for Class A shares. As of December 31, 2024, directors and executive officers collectively owned approximately 82% of the voting power of Olo's outstanding capital stock [3]. Group 2: Acquisition Details - On July 3, 2025, Olo announced a definitive agreement to be acquired by Thoma Bravo in an all-cash transaction, with shareholders set to receive $10.25 per share [3]. - The purchase price represents a 65% premium over Olo's unaffected share price of $6.20 as of April 30, 2025 [3]. Group 3: Legal Investigation - The investigation by BFA Law focuses on whether Olo's board of directors, executive officers, and CEO Noah H. Glass breached their fiduciary duties in connection with the merger [4]. - Current shareholders of Olo are encouraged to seek additional information regarding their legal options related to the merger [2][5]. Group 4: Law Firm Background - Bleichmar Fonti & Auld LLP is recognized as a leading international law firm specializing in securities class actions and shareholder litigation, with notable recoveries in past cases [6].